18 results
Thumbnail

D3.409 - Immunological Mechanisms in Treatment-Resistant Depression

Thumbnail

D3.413 - Basophil Activation Test Positivity and Response to Ciclosporin in Chronic Spontaneous Urticaria: A Real-World Exploratory Study

Thumbnail

D3.414 - Clinical and Laboratory Predictors of Basophil Activation Test Positivity in Chronic Spontaneous Urticaria: A Real-World Exploratory Study

Thumbnail

D3.416 - PEG-CUR Reduces Oxidative Stress and Total Methylation Induced by Cigarette Smoke in Epithelial Cells: Development of PEG-Curcumin Loaded Fast-Dissolving Microneedle Patches

Thumbnail

D3.398 - Primary Care Physicians’ Perspectives on Primary Immunodeficiency Diseases

Thumbnail

D3.401 - A mechanism for loss of biodiversity in the gut: Toxic effects and metabolic alterations of food additives on human fecal microbiome

Thumbnail

D3.404 - From CVID to CTLA-4 Haploinsufficiency: The Impact of Genetic Diagnosis on Targeted Therapy

Thumbnail

D3.407 - Angioedema: cause or consequence?

Thumbnail

D3.408 - When Angioedema Is Not Angioedema: EBV-Associated Lymphocytic Inflammation Mimicking Hereditary Angioedema

Thumbnail

D3.415 - Galectin-10 Expression in Plasma-Derived Extracellular Vesicles of Patients with Eosinophilic Esophagitis: a Pilot Study

Thumbnail

D1.437 - A Decade of Research on Janus Kinase Inhibitors in Atopic Dermatitis: A Global Bibliometric Analysis (2015–2024)

Thumbnail

D1.438 - Dupilumab for Moderate-to-Severe Atopic Dermatitis in Children and Adolescents: Real-Life Assessment of Efficacy and Safety

Thumbnail

D1.442 - Design and Preclinical Development of a Bispecific Antibody Targeting IL11 and TL1A

Thumbnail

D1.443 - Preclinical Development of a Dual LIGHT/TL1A Bispecific Antibody

Thumbnail

D1.447 - Comparison of Disease Duration, Remission, and Other Disease-Related Parameters with the Duration of Omalizumab Treatment in Patients with Chronic Spontaneous Urticaria

Thumbnail

D1.448 - Long-Term Efficacy and Stability of Lebrikizumab in Treating Face/Head and Neck Involvement in Patients with Moderate-to-Severe Atopic Dermatitis

Thumbnail

D1.449 - A Phase 2, Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Briquilimab in Adults with Chronic Urticaria (Trial in Progress)

Thumbnail

D1.439 - Urticaria Voices: Physician-reported perspectives of chronic urticaria care and its treatment in China (UV in China)